Radiopharm Theranostics hits enrollment milestone in brain metastases trial
Radiopharm Theranostics (NASDAQ:RADX), a developer of a world-class platform of radiopharmaceutical products, today announced it has completed enrollment in its U.S. Phase 2b imaging trial of RAD 101 (18F-FET).























